Core Viewpoint - The company maintains a stable financial condition with manageable debt risk despite a decrease in cash reserves and an increase in the debt-to-asset ratio [1] Group 1: Financial Performance - As of Q3 2025, the company reported a positive operating cash flow of 921 million [1] - The positive cash flow does not necessarily translate into an increase in cash reserves at the end of the period [1] Group 2: Debt Management - The company is actively managing its obligations, including payments to suppliers and equipment, which are not reflected in the operating cash flow [1] - The company perceives its debt risk as controllable and is focused on maintaining a healthy financial structure [1] Group 3: Fundraising Strategy - The company plans to raise 1 billion to support new business projects, aiming to avoid excessive use of operational funds and to optimize its capital structure [1] - The fundraising is aligned with the company's long-term development strategy [1]

Group 1 - The core viewpoint of the article is that the company is actively adjusting its business structure to enhance growth and meet market demands [1] - The company is focusing on sectors such as health care, medical beauty, rehabilitation, maternal and child services, assisted reproduction, and special needs services [1] - The company plans to establish specialized departments such as elderly care facilities, Huibin departments, and proton therapy to cater to market needs [1]

证券之星消息，国际医学(000516)02月05日在投资者关系平台上答复投资者关心的问题。 投资者提问：很多人投资与你们是因为股价低，但是股价低的原因大家却不知道，资产的价格是供求关 系决定的，低价代表产品没有竞争力也没有定价权和议价能力，请问贵公司国际医学的投资价值是什 么？ 国际医学回复：您好，感谢您对公司的关注。公司的核心投资价值在于稀缺的优质医疗资产，具体体现 在以下方面：公司以大健康医疗服务和现代医学技术转化应用为主业，拥有规模化的服务体系与区域内 优质的诊疗能力；公司旗下医疗机构拥有同步国际先进水平的硬件设备（即将投用的西安国际医学中心 医院质子治疗中心是西北地区首个质子放射治疗中心）；汇聚了由各学科带头人领衔的专业团队，旗下 医院已成为6所大学的附属或教学医院；公司旗下医院"综合医疗+特色专科"的业务模式，契合多元化健 康需求。谢谢！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The company International Medicine (000516) is facing challenges related to its stock performance and ongoing capital increase plans, amid concerns over major shareholder actions and industry policy changes [1][2][3] Group 1: Stock Performance - As of February 5, 2026, International Medicine's stock closed at 4.95 yuan, down 0.4%, with a turnover rate of 1.41%, trading volume of 311,800 shares, and a transaction value of 155 million yuan [1] - On the same day, there was a net outflow of 14.1651 million yuan from major funds, indicating a short-term reduction in holdings by institutional investors [3] Group 2: Capital Increase and Shareholder Concerns - The company is currently in the process of a non-public offering, but the specific issuance targets have not yet been determined, leading to investor concerns about potential shareholder dilution and stock price impacts [2] - Major shareholder Century Xinyuan has pledged 82.07% of its shares as of mid-January 2026, raising questions about control and financial stability, although the company asserts that the risk is manageable [2] Group 3: Operational Strategies - In response to ongoing healthcare policy reforms, the company is focusing on enhancing operational efficiency and cost control, particularly in specialized medical fields such as neurology, cardiology, and oncology [2][3] - The company is also exploring differentiated business strategies in areas like aesthetic medicine, rehabilitation, and elder care to build competitive advantages and improve service value [2]

证券之星消息，截至2026年2月5日收盘，国际医学(000516)报收于4.95元，下跌0.4%，换手率1.41%， 成交量31.18万手，成交额1.55亿元。 近5日资金流向一览见下表： 该股最近90天内共有2家机构给出评级，增持评级2家；过去90天内机构目标均价为5.5。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 国际医学2025年三季报显示，前三季度公司主营收入29.95亿元，同比下降16.94%；归母净利润-2.94亿 元，同比下降38.45%；扣非净利润-3. ...

证券日报网讯 2月5日，国际医学（000516）在互动平台回答投资者提问时表示，面对当前行业政策， 特别是医保支付改革的深化，公司与旗下医疗机构坚持规范运营，不断强化成本管控和效率提升，已在 优势专科建设、差异化业务布局上采取了一系列措施，实现了运营效率的持续优化、经营业绩的改善提 升。 ...

证券日报网讯 2月5日，国际医学（000516）在互动平台回答投资者提问时表示，公司控股股东及一致 行动人资信状况良好，具备较强的资金偿还能力，质押风险可控。 ...

证券日报网讯 2月5日，国际医学在互动平台回答投资者提问时表示，关于公司2026年度的经营与财务 情况，请留意公司后续披露的定期报告。 （文章来源：证券日报） ...

证券日报网讯 2月5日，国际医学在互动平台回答投资者提问时表示，"国际医学"的名称凝聚了公司"汇 聚人类生命科学智慧，同步国际先进诊疗水平"的愿景。 （文章来源：证券日报） ...

Core Viewpoint - The company is adapting to industry policy adjustments, particularly the ongoing deepening of medical insurance payment reforms, by strengthening its specialized departments and exploring new service areas to build a competitive advantage and enhance service value [1] Group 1: Specialized Departments - The company is focusing on enhancing its strengths in specialized departments such as neurology, cardiovascular, digestive, thoracic, oncology, hematology, and orthopedics to create a solid "moat" [1] - Continuous improvement in operational efficiency and business performance is being achieved through clinical pathway management and promotion of day surgery [1] Group 2: New Service Areas - The company is actively exploring and laying out services in aesthetic medicine, rehabilitation, maternal and child health, health management, traditional Chinese medicine, assisted reproduction, mental health, special needs services, elderly care, and proton therapy [1] - A differentiated strategy is being employed to construct competitive advantages in these new service areas [1] Group 3: Operational Efficiency - The company and its subsidiaries are committed to standardized operations, which include a series of measures aimed at cost control and efficiency enhancement [1] - The focus on operational efficiency is leading to continuous optimization and improvement in business performance [1]